{
    "clinical_study": {
        "@rank": "132687", 
        "acronym": "SUMMIT", 
        "arm_group": [
            {
                "arm_group_label": "Sorafenib tablets", 
                "arm_group_type": "Experimental", 
                "description": "Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Placebo tablets", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of his study is to evaluate the efficacy and safety of Sorafenib versus placebo\n      in subjects with locally advanced medullary thyroid cancer (MTC). The primary study\n      objective is to compare the Progression-free Survival (PFS) of the Sorafenib treatment group\n      with the placebo treatment group in patients with advanced MTC."
        }, 
        "brief_title": "Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Medullary Thyroid Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Inpatient or outpatient \u2265 18 years of age\n\n          -  Histologically confirmed medullary thyroid carcinoma\n\n          -  Recurrent or persistent local disease and/or distant metastases\n\n          -  No more than one prior line of systemic therapy\n\n          -  Best available supportive care to control (endocrine) symptoms\n\n          -  At least one defined lesion in CT or MRI evaluable for Response Evaluation Criteria\n             in Solid Tumors (RECIST v1.1), or at least one defined lesion in CT or MRI not\n             evaluable by RECIST in combination with elevated tumour markers\n\n          -  Progression within previous 12 months\n\n          -  Hb > 8g/dl, white blood cells (WBC) >3.000 cells/mm\u00b3 (ANC > 1.500 cells/mm\u00b3),\n             platelets > 100.000 cells/mm\u00b3, bilirubin < 2mg/dl, alanine aminotransferase (ALT) and\n             aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)\n\n          -  Performance status: WHO \u2264 2; Karnofsky index \u2265 50%\n\n          -  Sufficient renal function (creatinin <1.5 mg/dl and creatinin clearance > 30ml/min)\n\n          -  International normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 x\n             ULN\n\n          -  No acute infections\n\n          -  Staging studies (MRT or CT and Calcitonin or CEA) completed within four weeks of\n             protocol randomisation\n\n          -  Women of childbearing potential with negative serum pregnancy test\n\n          -  Women and men of childbearing potential using adequate contraception\n\n          -  Signed and dated written informed consent\n\n        Exclusion Criteria:\n\n          -  Unresolved toxicity (i.e. neurotoxicity) attributed to any prior therapy higher than\n             National Cancer Institute-Common Toxicity Criteria for Adverse Effects (NCI-CTCAE\n             version 4) Grade 2 (excluding cases of alopecia)\n\n          -  Patients with history of allergic or hypersensitivity reaction to study drug or\n             placebo or their excipients\n\n          -  Current participation in another investigational trial\n\n          -  Patients with significant cardiovascular disease\n\n          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy other than\n             beta-blockers or digoxin\n\n          -  Congenital long corrected QT interval (QTc) syndrome, history of drug induced QTc\n             prolongation, or QTc interval unmeasurable or more than 450 ms\n\n          -  Abnormal serum electrolytes such as potassium, magnesium and calcium\n\n          -  Uncontrolled hypertension, despite optimal management\n\n          -  Major surgery, open biopsy, or significant traumatic injury within 30 days prior to\n             randomization\n\n          -  Non-healing wound, ulcer, or bone fracture\n\n          -  Evidence or history of bleeding diathesis or coagulopathy disorder\n\n          -  Hemorrhage/bleeding event \u2265 Grade 3\n\n          -  Thrombotic or embolic events including transient ischemic attacks within the past 6\n             months\n\n          -  Subjects with symptomatic brain metastases or Subjects with brain metastases under\n             corticosteroid treatment\n\n          -  Pregnant or breast-feeding patients\n\n          -  Patients with uncontrolled infections\n\n          -  Known HIV infection or infection with hepatitis B or C\n\n          -  Immunosuppression\n\n          -  Subjects with seizure disorder requiring medication \u2022 Subjects undergoing renal\n             dialysis\n\n          -  Substance abuse, medical, psychological or social conditions that may interfere with\n             the subject's participation in the study or evaluation of the study results\n\n          -  Any malabsorption condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736878", 
            "org_study_id": "EARL-2", 
            "secondary_id": "2011-006250-90"
        }, 
        "intervention": {
            "arm_group_label": [
                "Sorafenib tablets", 
                "Placebo tablets"
            ], 
            "intervention_name": "Sorafenib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Medullary Thyroid Carcinoma", 
            "Sorafenib", 
            "Efficacy"
        ], 
        "lastchanged_date": "May 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ulm", 
                    "country": "Germany", 
                    "state": "Baden-Wuerttemberg", 
                    "zip": "D-89081"
                }, 
                "name": "University Hospital Ulm, Clinic for Nuclear Medicine"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma", 
        "other_outcome": {
            "description": "The proportion of surviving patients in the Sorafenib group and the Placebo group will be compared.", 
            "measure": "Overall Survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "from the date of randomisation until the date of death due to any cause. Final assessment at the end of study after approximately 36 months."
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Austria : Federal Ministry for Labour, Health, and Social Affairs"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The proportion of patients with PFS in the Sorafenib group and the Placebo group will be compared by log rank test and Kaplan-Meier plot.", 
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "from the date of randomisation until the date of radiological or biochemical progression or death. An average of 9 months is assumed."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736878"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The average TTP in the Sorafenib group and the Placebo group will be compared.", 
            "measure": "Time to Progression (TPP)", 
            "safety_issue": "No", 
            "time_frame": "from the date of randomisation until the date of confirmed radiological or biochemical progression. An average of 9 months is assumed."
        }, 
        "source": "Eanm Research Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eanm Research Ltd", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013", 
        "why_stopped": "Study was withdrawn due to unanticipated hassle in patient recruitment."
    }
}